Sarepta Therapeutics (SRPT) Tops Q3 EPS by 76c

Sarepta Therapeutics (NASDAQ: SRPT) reported Q3 EPS of ($0.46), $0.76 better than the analyst estimate of ($1.22). Revenue for the quarter came in at $331.8 million versus the consensus estimate of $285.83 million.

For earnings history and earnings-related data on Sarepta Therapeutics (SRPT) click here.

You May Also Be Interested In

• onsemi downgraded by TD Cowen after Synaptics deal clouds growth story
• Citizens Starts Six Flags Entertainment (FUN) at Market Outperform
• RBC Capital Upgrades Central Asia Metals plc (CAML:LN) to Sector Perform